文献速递消化道肿瘤放疗胸部肿瘤放疗

倾向性匹配研究:局部晚期食管癌手术与术后放疗的比较

Propensity-matched study on locally advanced esophageal cancer: surgery versus post-operative radiotherapy.
PubMed 文献 · Radiat Oncol · 2024-09-27

这项来自两个学术中心的回顾性队列纳入506例初始接受食管切除术且病理分期为T3-4的胸段食管鳞状细胞癌患者,其中251例单纯手术、255例接受根治术后放疗。中位随访49.1个月,术后放疗较单纯手术显著改善5年总生存率(53.8% vs 25.3%;p < 0.001)和5年无病生存率(45.3% vs 8.5%;p < 0.001),倾向性评分匹配后差异仍存在(两者p < 0.001)。术后放疗组治疗失败率46.7%低于单纯手术组90.0%(p < 0.001),局部区域复发率9.4%低于54.1%(p < 0.001)。

要点

  • 术后放疗组5年总生存率53.8% vs 单纯手术组25.3%,p < 0.001。
  • 术后放疗组5年无病生存率45.3% vs 单纯手术组8.5%,p < 0.001。
  • 术后放疗组局部区域复发率9.4% vs 单纯手术组54.1%,p < 0.001。

核心结论

  • 在未接受新辅助放化疗的局部晚期T3-4胸段食管鳞状细胞癌患者中,术后放疗与改善生存和减少复发相关。
  • 作者认为术后放疗可作为未接受新辅助放化疗的局部晚期胸段食管鳞状细胞癌患者的挽救治疗。

研究设计与样本

  • 来自两个学术中心的回顾性队列,纳入初始接受食管切除术且病理分期为T3-4的患者,共506例,其中251例单纯手术、255例接受根治术后放疗。
  • 采用Kaplan-Meier法构建生存结局,log-rank检验评估生存显著性,并使用倾向性评分匹配(PSM)平衡潜在选择偏倚。

主要发现

  • 中位随访49.1个月,术后放疗组5年总生存率53.8% vs 单纯手术组25.3%(p < 0.001)。
  • 术后放疗组5年无病生存率45.3% vs 单纯手术组8.5%(p < 0.001)。
  • 倾向性评分匹配后,术后放疗组与单纯手术组的生存差异仍存在(两者p < 0.001)。
  • 术后放疗组治疗失败率46.7% vs 单纯手术组90.0%(p < 0.001)。
  • 术后放疗组局部区域复发率9.4% vs 单纯手术组54.1%(p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为术后放疗可作为未接受新辅助放化疗的局部晚期胸段食管鳞状细胞癌患者的挽救治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aims to delineate the long-term outcomes and recurrence patterns of locally advanced thoracic esophageal squamous cell carcinoma (TESCC) patients managed with or without postoperative radiotherapy (PORT). METHODS: A retrospective cohort from two academic centers, encompassing patients who initially underwent esophagectomy and were pathologically staged T3-4, was analyzed. Survival outcomes were constructed using Kaplan-Meier method, with survival significance was evaluated using the log-rank test. Propensity score matching (PSM) was utilized to balance potential selection bias. RESULTS: Among the 506 patients, 251 underwent surgery alone and 255 received radiotherapy following radical surgery. With a median follow-up of 49.1 months, PORT significantly improved 5-year overall survival (53.8% vs. 25.3%; p < 0.001) and 5-year disease-free survival rates (45.3% vs. 8.5%; p < 0.001) compared to surgery alone. These differences in survival outcomes persisted even after PSM (p < 0.001 for both). Treatment failure was significantly less frequent in the PORT group (46.7%) compared to the surgery-only group (90.0%; p < 0.001), with corresponding reductions in locoregional recurrence (9.4% vs. 54.1%; p < 0.001). This underscores the significant association between PORT and disease control. CONCLUSION: The absence of neoadjuvant chemoradiotherapy highlights the importance of PORT in improving survival and reducing recurrence in advanced T3-4 TESCC patients. This study underscores the importance of PORT as a salvage treatment for locally advanced TESCC patients without neoadjuvant chemoradiotherapy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zeng Y, Su X, Zhou T, et al. Propensity-matched study on locally advanced esophageal cancer: surgery versus post-operative radiotherapy. Radiat Oncol. 2024. PMID: 39334405. doi:10.1186/s13014-024-02528-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。